

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCES AND/OR AMINO ACID SEQUENCE DISCLOSURES**

**In the Specification**

Please replace the paragraph bridging pages 58 and 59 with the following paragraph.

**--RNA extraction and RT-PCR.** Total RNA of  $10^6$  cells was isolated according to RNeasy<sup>TM</sup> B protocol (AMS Bio, UK). cDNA synthesis of the whole RNA pellet was performed in a 40  $\mu$ l reaction. The dissolved RNA pellet was first incubated with 2  $\mu$ g oligo-dT 12-18 primer (Life Technologies, Scotland) at 65°C for 10 min, followed by a 1 h incubation at 42°C with a mixture of 50 U of murine leukemia virus (MuLV) reverse transcriptase, 10 mM dithiothreitol, 1 mM dNTP (Boehringer Mannheim, UK), 40 U RNase inhibitor (Promega, UK). Five  $\mu$ l of the cDNA preparation was used for PCR amplification in a 50  $\mu$ l volume of final reaction mixture containing 2.5 U of Taq DNA polymerase (Qiagen, UK), 1mM dNTP, 20 OD/ml primer. Amplification of the human WT1 coding region was achieved using sense primers located in exon 7 (21mer 5'-ggc atc tga gac cag tga gaa-3') (SEQ ID NO:6) and antisense primers in exon 10 (22mer 5' gag agt cag act tga aag cag t-3') (SEQ ID NO:7). Expected size for WT1 PCR product is 482bp. RNA integrity was verified by amplifying the human *c-abl* gene in every sample using intron-spanning primers: 22mer sense 5'-ccc aac ctt ttc gtt gca ctg t-3' (SEQ ID NO:8); 22mer antisense 5'-cgg ctc tcg gag gag acg atg a-3' (SEQ ID NO:9). Expected size of *c-abl* PCR product is 385bp. Hot-start PCR was performed for 35 cycles with a thermal cycler (Techne Genius, Cambridge) under the following conditions (same for ABL and WT1 amplification): denaturing at 95°C for 1 min, primer annealing at 56°C for 1 min and chain elongation at 72°C for 2 min. The cycling was initiated by a 5 min denaturation step at 95°C to heat inactivate the reverse transcriptase and terminated by a 10 min final extension at 72°C. All RT-PCRs were performed at least twice and negative control (no cDNA) and positive control (cDNA from the WT1 expressing leukemic cell line BV173) were included in every experiment. PCR products were electrophoresed through 1.5% agarose gels. --

U.S.S.N. 09/625,963

Filed: July 26, 2000

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCES AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Please replace the abstract of the specification with the following abstract.

--A peptide comprising the amino acid sequence RMFPNAPYL (SEQ ID NO:1) or a portion or variant thereof provided that the peptide is not intact human WT-1 polypeptide or a peptide comprising the amino acid sequence CMTWNQMNL (SEQ ID NO:2) or a portion or variant thereof provided that the peptide is not intact human WT-1 polypeptide or a peptide comprising the amino acid sequence HLMPFPGPLL (SEQ ID NO:3) or a portion or variant thereof provided that the peptide is not intact human gata-1 polypeptide, and polynucleotides encoding these peptides. The peptides and polynucleotides are useful as cancer vaccines.--